JPRN-UMIN000001608
Completed
未知
Establishment of surveillance system for the longstanding ulcerative colitis patients Comparative study of efficacy for the targeted biopsy and the step biopsy - Establishment of surveillance system for the longstanding ulcerative colitis patients
Teikyo University School of Medicine0 sites200 target enrollmentJanuary 5, 2009
Conditionslcerative colitis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- lcerative colitis
- Sponsor
- Teikyo University School of Medicine
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients who have past history of colon cancer and/or ulcerative colitis associated neoplasm 2\) Patients suspected of bleeding diathesis or coagulation abnormality 3\) Renal dysfunction (Cre \> 1\.2 mg/dl) 4\)Pregnancy or breast feeding 5\)Otherwise, patiesnts who investigator judged ineligible to register
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Establishment of the surveillance system exploring risk factors for emergency transportation outside a remote island.chronic illness, osteoporosis, and patients with potentially high risk for emergency admissions.JPRN-UMIN000033313The Institute of Medical Science, the University of Tokyo2,000
Not yet recruiting
Not Applicable
Establishment of surveillance system for individuals diagnosed with COVID-19.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/08/027078Tata Memorial Hospital
Recruiting
Not Applicable
A prospective registry for the surveillance to improve the management of coronary artery disease: Juntendo Physicians Alliance for Clinical Trials (J-PACT) PCI database.Coronary artery diseaseJPRN-UMIN000035587Juntendo University, Graduate School of Medicine Department of Cardiovascular Biology and Medicine10,000
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Not possible to specifyEUCTR2020-001762-11-HUCorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.EUCTR2020-001762-11-GBCorbus Pharmaceuticals, Inc.100